Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

1.

89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding.

van Brummelen EMJ, Huisman MC, de Wit-van der Veen LJ, Nayak TK, Stokkel MPM, Mulder ER, Hoekstra OS, Vugts DJ, Van Dongen GAMS, Verheul HM, Evers S, Tessier JJL, Saro J, Schellens JHM, Menke-van der Houven van Oordt CW.

Oncotarget. 2018 May 15;9(37):24737-24749. doi: 10.18632/oncotarget.25343. eCollection 2018 May 15.

2.

Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images.

Jauw YWS, Heijtel DF, Zijlstra JM, Hoekstra OS, de Vet HCW, Vugts DJ, Verheul HM, Boellaard R, Zweegman S, van Dongen GAMS, der Houven van Oordt CWM, Lammertsma AA, Huisman MC.

Mol Imaging Biol. 2018 Apr 30. doi: 10.1007/s11307-018-1200-4. [Epub ahead of print]

PMID:
29713958
3.

Identification of the allosteric P2X7 receptor antagonist [11C]SMW139 as a PET tracer of microglial activation.

Janssen B, Vugts DJ, Wilkinson SM, Ory D, Chalon S, Hoozemans JJM, Schuit RC, Beaino W, Kooijman EJM, van den Hoek J, Chishty M, Doméné A, Van der Perren A, Villa A, Maggi A, Molenaar GT, Funke U, Shevchenko RV, Baekelandt V, Bormans G, Lammertsma AA, Kassiou M, Windhorst AD.

Sci Rep. 2018 Apr 26;8(1):6580. doi: 10.1038/s41598-018-24814-0.

4.

PET Imaging of Microglial Activation-Beyond Targeting TSPO.

Janssen B, Vugts DJ, Windhorst AD, Mach RH.

Molecules. 2018 Mar 8;23(3). pii: E607. doi: 10.3390/molecules23030607. Review.

5.

Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody.

Jauw YWS, Huisman MC, Nayak TK, Vugts DJ, Christen R, Naegelen VM, Ruettinger D, Heil F, Lammertsma AA, Verheul HMW, Hoekstra OS, van Dongen GAMS, Menke-van der Houven van Oordt CW.

EJNMMI Res. 2018 Jan 22;8(1):6. doi: 10.1186/s13550-018-0358-8.

6.

Pharmacological Evaluation of Novel Bioisosteres of an Adamantanyl Benzamide P2X7 Receptor Antagonist.

Wilkinson SM, Barron ML, O'Brien-Brown J, Janssen B, Stokes L, Werry EL, Chishty M, Skarratt KK, Ong JA, Hibbs DE, Vugts DJ, Fuller S, Windhorst AD, Kassiou M.

ACS Chem Neurosci. 2017 Nov 15;8(11):2374-2380. doi: 10.1021/acschemneuro.7b00272. Epub 2017 Aug 25.

PMID:
28841278
7.

Fluorine-18 labelled building blocks for PET tracer synthesis.

van der Born D, Pees A, Poot AJ, Orru RVA, Windhorst AD, Vugts DJ.

Chem Soc Rev. 2017 Jul 31;46(15):4709-4773. doi: 10.1039/c6cs00492j. Review.

PMID:
28608906
8.

Non invasive imaging assessment of the biodistribution of GSK2849330, an ADCC and CDC optimized anti HER3 mAb, and its role in tumor macrophage recruitment in human tumor-bearing mice.

Alsaid H, Skedzielewski T, Rambo MV, Hunsinger K, Hoang B, Fieles W, Long ER, Tunstead J, Vugts DJ, Cleveland M, Clarke N, Matheny C, Jucker BM.

PLoS One. 2017 Apr 27;12(4):e0176075. doi: 10.1371/journal.pone.0176075. eCollection 2017.

9.

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.

Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, Lang S, Roemmele M, Hofer T, van Puijenbroek E, Wittig D, Moser S, Ast O, Brünker P, Gorr IH, Neumann S, de Vera Mudry MC, Hinton H, Crameri F, Saro J, Evers S, Gerdes C, Bacac M, van Dongen G, Moessner E, Umaña P.

Oncoimmunology. 2017 Jan 11;6(3):e1277306. doi: 10.1080/2162402X.2016.1277306. eCollection 2017.

10.

ESPMIS: Helping Young Scientists Navigate the Molecular Imaging Landscape.

Zeglis BM, Vugts DJ.

Mol Imaging Biol. 2017 Jun;19(3):325-327. doi: 10.1007/s11307-017-1053-2.

PMID:
28194633
11.

Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.

Jauw YW, Zijlstra JM, de Jong D, Vugts DJ, Zweegman S, Hoekstra OS, van Dongen GA, Huisman MC.

PLoS One. 2017 Jan 6;12(1):e0169828. doi: 10.1371/journal.pone.0169828. eCollection 2017.

12.

PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer.

van Loon J, Even AJG, Aerts HJWL, Öllers M, Hoebers F, van Elmpt W, Dubois L, Dingemans AC, Lalisang RI, Kempers P, Brans B, Winnepenninckx V, Speel EJ, Thunnissen E, Smits KM, Boellaard R, Vugts DJ, De Ruysscher D, Lambin P.

Radiother Oncol. 2017 Feb;122(2):267-273. doi: 10.1016/j.radonc.2016.11.020. Epub 2016 Dec 21.

PMID:
28012793
13.

Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach.

Even AJ, Hamming-Vrieze O, van Elmpt W, Winnepenninckx VJ, Heukelom J, Tesselaar ME, Vogel WV, Hoeben A, Zegers CM, Vugts DJ, van Dongen GA, Bartelink H, Mottaghy FM, Hoebers F, Lambin P.

Oncotarget. 2017 Jan 17;8(3):3870-3880. doi: 10.18632/oncotarget.13910.

14.

Molecular Drug Imaging: 89Zr-Bevacizumab PET in Children with Diffuse Intrinsic Pontine Glioma.

Jansen MH, Veldhuijzen van Zanten SEM, van Vuurden DG, Huisman MC, Vugts DJ, Hoekstra OS, van Dongen GA, Kaspers GL.

J Nucl Med. 2017 May;58(5):711-716. doi: 10.2967/jnumed.116.180216. Epub 2016 Oct 20.

15.

Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET.

Vugts DJ, Klaver C, Sewing C, Poot AJ, Adamzek K, Huegli S, Mari C, Visser GW, Valverde IE, Gasser G, Mindt TL, van Dongen GA.

Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):286-295. doi: 10.1007/s00259-016-3499-x. Epub 2016 Aug 30.

16.

Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models.

Jansen MH, Lagerweij T, Sewing AC, Vugts DJ, van Vuurden DG, Molthoff CF, Caretti V, Veringa SJ, Petersen N, Carcaboso AM, Noske DP, Vandertop WP, Wesseling P, van Dongen GA, Kaspers GJ, Hulleman E.

Mol Cancer Ther. 2016 Sep;15(9):2166-74. doi: 10.1158/1535-7163.MCT-15-0558. Epub 2016 Jun 20.

17.

HDL mimetic CER-001 targets atherosclerotic plaques in patients.

Zheng KH, van der Valk FM, Smits LP, Sandberg M, Dasseux JL, Baron R, Barbaras R, Keyserling C, Coolen BF, Nederveen AJ, Verberne HJ, Nell TE, Vugts DJ, Duivenvoorden R, Fayad ZA, Mulder WJM, van Dongen GAMS, Stroes ESG.

Atherosclerosis. 2016 Aug;251:381-388. doi: 10.1016/j.atherosclerosis.2016.05.038. Epub 2016 May 27.

18.

Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?

Jauw YW, Menke-van der Houven van Oordt CW, Hoekstra OS, Hendrikse NH, Vugts DJ, Zijlstra JM, Huisman MC, van Dongen GA.

Front Pharmacol. 2016 May 24;7:131. doi: 10.3389/fphar.2016.00131. eCollection 2016. Review.

19.

Imaging of neuroinflammation in Alzheimer's disease, multiple sclerosis and stroke: Recent developments in positron emission tomography.

Janssen B, Vugts DJ, Funke U, Molenaar GT, Kruijer PS, van Berckel BN, Lammertsma AA, Windhorst AD.

Biochim Biophys Acta. 2016 Mar;1862(3):425-41. doi: 10.1016/j.bbadis.2015.11.011. Epub 2015 Nov 28.

20.

89Zr-cetuximab PET imaging in patients with advanced colorectal cancer.

Menke-van der Houven van Oordt CW, Gootjes EC, Huisman MC, Vugts DJ, Roth C, Luik AM, Mulder ER, Schuit RC, Boellaard R, Hoekstra OS, van Dongen GA, Verheul HM.

Oncotarget. 2015 Oct 6;6(30):30384-93. doi: 10.18632/oncotarget.4672.

Supplemental Content

Loading ...
Support Center